Having trouble accessing articles? Reset your cache.

ARQ 197: SPA received

ArQule received an SPA from FDA for a planned double-blind Phase III trial to evaluate ARQ 197 plus Tarceva

Read the full 191 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE